Toponomics: studying protein-protein interactions and protein networks in intact tissue.

The function of a protein is determined on several levels including the genome, transcriptome, proteome, and the recently introduced toponome. The toponome describes the topology of all proteins, protein complexes and protein networks which constitute and influence the microenvironment of a given protein. It has long been known that cellular function or dysfunction of proteins strongly depends on their microenvironment and even small changes in protein arrangements can dramatically alter their activity/function. Thus, deciphering the topology of the multi-dimensional networks which control normal and disease-related pathways will give a better understanding of the mechanisms underlying disease development. While various powerful proteomic tools allow simultaneous quantification of proteins, only a limited number of techniques are available to visualize protein networks in intact cells and tissues. This review discusses a novel approach to map and decipher functional molecular networks of proteins in intact cells or tissues. Multi-epitope-ligand-cartography (MELC) is an imaging technology that identifies and quantifies protein networks at the subcellular level of morphologically-intact specimens. This immunohistochemistry-based method allows serial visualization and biomathematical analysis of up to 100 cellular components using fluorescence-labelled tags. The resulting toponome maps, simultaneously ranging from the subcellular to the supracellular scale, have the potential to provide the basis for a mathematical description of the dynamic topology of protein networks, and will complement current proteomic data to enhance the understanding of physiological and pathophysiological cell functions.

[1]  Walter Schubert,et al.  Fluorescence detection of protein clusters in individual cells and tissue sections by using toponome imaging system: sample preparation and measuring procedures , 2007, Nature Protocols.

[2]  N. Goldstein,et al.  Target validation and drug discovery using genomic and protein–protein interaction technologies , 2002, Expert opinion on therapeutic targets.

[3]  A. Sorkin,et al.  Endocytosis and intracellular trafficking of ErbBs. , 2009, Experimental cell research.

[4]  W. Schubert,et al.  Analyzing proteome topology and function by automated multidimensional fluorescence microscopy , 2006, Nature Biotechnology.

[5]  D. Hochstrasser,et al.  From Proteins to Proteomes: Large Scale Protein Identification by Two-Dimensional Electrophoresis and Arnino Acid Analysis , 1996, Bio/Technology.

[6]  R. Falk,et al.  Approaches for systematic proteome exploration. , 2007, Biomolecular engineering.

[7]  J. Keene,et al.  The ribonome: a dominant force in co‐ordinating gene expression , 2009, Biology of the cell.

[8]  F. Hofmann,et al.  Cysteine-Rich Protein 2, a Novel Downstream Effector of cGMP/cGMP-Dependent Protein Kinase I-Mediated Persistent Inflammatory Pain , 2008, The Journal of Neuroscience.

[9]  Henning Hofmeister,et al.  In‐situ‐topoproteome analysis of cutaneous lymphomas: Perspectives of assistance for dermatohistologic diagnostics by Multi Epitope Ligand Cartography (MELC) , 2008 .

[10]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[11]  R. Aebersold,et al.  Mass spectrometry-based proteomics , 2003, Nature.

[12]  Qingming Luo,et al.  Mass spectrometry in systems biology: an overview. , 2008, Mass spectrometry reviews.

[13]  Henning Hofmeister,et al.  Comparative in situ topoproteome analysis reveals differences in patch test‐induced eczema: cytotoxicity‐dominated nickel versus pleiotrope pollen reaction , 2009, Experimental dermatology.

[14]  D. Figeys Mapping the human protein interactome , 2008, Cell Research.

[15]  L. Philipsen,et al.  Systematic high-content proteomic analysis reveals substantial immunologic changes in colorectal cancer. , 2008, Cancer research.

[16]  B. Bonnekoh,et al.  Topo-Proteomic in situ Analysis of Psoriatic Plaque under Efalizumab Treatment , 2007, Skin Pharmacology and Physiology.

[17]  G. Geisslinger,et al.  The IKK‐NF‐κB pathway: a source for novel molecular drug targets in pain therapy? , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  Anirvan Ghosh,et al.  Regulation of AMPA receptor recruitment at developing synapses , 2008, Trends in Neurosciences.

[19]  Nikolai Kley,et al.  Investigating the molecular basis of drug action and response: chemocentric genomics and proteomics. , 2006, Current drug targets.

[20]  Christian Stephan,et al.  Interlocking transcriptomics, proteomics and toponomics technologies for brain tissue analysis in murine hippocampus , 2008, Proteomics.

[21]  Joanna Owens 2006 drug approvals: finding the niche , 2007, Nature Reviews Drug Discovery.

[22]  S. Grant,et al.  Neuropathic Sensitization of Behavioral Reflexes and Spinal NMDA Receptor/CaM Kinase II Interactions Are Disrupted in PSD-95 Mutant Mice , 2003, Current Biology.

[23]  B. Bonnekoh,et al.  The CD11a Binding Site of Efalizumab in Psoriatic Skin Tissue as Analyzed by Multi-Epitope Ligand Cartography Robot Technology , 2006, Skin Pharmacology and Physiology.

[24]  L. Philipsen,et al.  Ulcerative Colitis Response Profiles in Crohn's Disease and Mucosa Reveals Distinctive Immune Proteomic Analysis of the Inflamed Intestinal , 2007 .

[25]  Steven J Brown,et al.  Sphingosine 1-phosphate receptor signaling. , 2009, Annual review of biochemistry.

[26]  Gerd Geisslinger,et al.  Toponomics analysis of drug-induced changes in arachidonic acid-dependent signaling pathways during spinal nociceptive processing. , 2009, Journal of proteome research.

[27]  E. Golemis,et al.  Resolving the network of cell signaling pathways using the evolving yeast two-hybrid system. , 2008, BioTechniques.

[28]  Walter Schubert,et al.  Topological proteomics, toponomics, MELK-technology. , 2003, Advances in biochemical engineering/biotechnology.

[29]  Harald Gollnick,et al.  Profiling lymphocyte subpopulations in peripheral blood under efalizumab treatment of psoriasis by multi epitope ligand cartography (MELC) robot microscopy. , 2006, European journal of dermatology : EJD.

[30]  L. Langeberg,et al.  The where's and when's of kinase anchoring. , 2006, Trends in biochemical sciences.

[31]  Anne-Claude Gavin,et al.  The social network of a cell: recent advances in interactome mapping. , 2008, Biotechnology annual review.

[32]  C. Rongo,et al.  The Ubiquitin Ligase RPM-1 and the p38 MAPK PMK-3 Regulate AMPA Receptor Trafficking , 2009, PloS one.

[33]  Heribert Hirt,et al.  Towards functional phosphoproteomics by mapping differential phosphorylation events in signaling networks , 2008, Proteomics.

[34]  Kankan Wang,et al.  Transcriptome and proteome analyses of drug interactions with natural products. , 2008, Current drug metabolism.

[35]  Nicola Pimpinelli,et al.  WHO-EORTC classification for cutaneous lymphomas. , 2005, Blood.

[36]  BrainProfileDB – a platform for integration of functional genomics data , 2008, Proteomics.

[37]  K. Scholich,et al.  Toponomics Analysis of Functional Interactions of the Ubiquitin Ligase PAM (Protein Associated with Myc) during Spinal Nociceptive Processing*S , 2008, Molecular & Cellular Proteomics.

[38]  Michael Meyer-Hermann,et al.  Geometrically Repatterned Immunological Synapses Uncover Formation Mechanisms , 2006, PLoS Comput. Biol..